Research Proven Benefits of
FlexC MOVE

Research Proven Benefits of
FlexC MOVE

The following are extracted from published clinical studies, in-house studies, and/or case studies and are for reference purposes only. This does not imply that the product from Lifestream Group Pte Ltd is claimed to replicate the same results produced in the studies. This information is not a substitute for professional medical advice, diagnosis, or treatment. If you have any questions about a medical condition, please consult your physician or other qualified healthcare providers. Any statements or claims made have not been evaluated by the relevant regulatory bodies and are not intended to diagnose, treat, cure, or prevent any disease. By using the Site, you agree that you have read and acknowledge the above and the Terms of Use for this Site.

The following are extracted from published clinical studies, in-house studies, and/or case studies and are for reference purposes only. This does not imply that the product from Lifestream Group Pte Ltd is claimed to replicate the same results produced in the studies. This information is not a substitute for professional medical advice, diagnosis, or treatment. If you have any questions about a medical condition, please consult your physician or other qualified healthcare providers. Any statements or claims made have not been evaluated by the relevant regulatory bodies and are not intended to diagnose, treat, cure, or prevent any disease. By using the Site, you agree that you have read and acknowledge the above and the Terms of Use for this Site.

1) Relieve knee joint discomfort

Study 1: In this clinical trial, 96 healthy adults (aged 20 to 55 years old) who experienced knee discomfort with physical activity (no history of osteoarthritis or joint diseases) were orally administered 40 mg of UC-II® undenatured type II collagen or placebo daily for 24 weeks and range of motion (ROM) flexion and extension were measured using a digital goniometer.

Compared to baseline, UC-II® undenatured type II collagen significantly increased knee ROM extension by 2.21 degrees (p = 0.0061). Besides, UC-II® significantly increased knee ROM flexion (flexibility) 15 times more than placebo (3.23 degrees vs. 0.21 degrees, p=0.025) as early as eight weeks. These findings suggest that daily supplementation of 40mg of UC-II® helps improve knee joint flexibility and extensibility in healthy subjects with activity-related joint discomfort.

Study 2: In this clinical trial, 96 healthy adults (aged 20 to 55 years) who experienced knee discomfort with physical activity were orally administered 40 mg of UC-II® undenatured type II collagen or placebo for 24 weeks and the impact of UC-II® on joint comfort and mobility was determined. Compared to placebo, UC-II® significantly decreased knee discomfort when twisting / pivoting the knee, walking downstairs and walking on a flat surface. Besides, UC-II® significantly reduced post-physical activity joint discomfort. In addition, subjects who were administered with UC-II® walked 747 more steps or 0.4 km more per day, compared to placebo. These findings suggest the efficacy of UC-II® in reducing knee joint discomfort and improving mobility in healthy subjects.

Study 3: In this clinical trial, 17 healthy adults aged ≥50 years were orally administered 40mg of UC-II® undenatured type II collagen or placebo for 120 days and their knee discomfort was determined using KOOS (Knee Injury and Osteoarthritis Outcome Score) questionnaire. UC-II® significantly decreases joint discomfort during activities of daily living. Compared to placebo, UC-II® significantly reduced joint discomfort during climbing, walking up and down stairs, bending and squating. These findings suggest that UC-II® supplementation has the potential to help improve knee joint function, mobility, flexibility, free movements and performance of daily activities for those experience exercise-induced knee pain.

Study 4: In this study, 5 women aged 58 to 78 years old with significant joint pain were orally administered 10 mg/day UC-II® for 42 days. Resulted showed significant pain reduction, including morning stiffness, stiffness following periods of rest, pain that worsens with use of the affected joint and loss of joint range of motion. These findings suggest the use of UC-II® in mitigating joint inflammatory conditions (Int J Clin Pharmacol Res.22(3-4):101-10 (2002)).

2) Manage osteoarthritis symptoms

Study 1: In an in-house double-blind, placebo-controlled clinical study, 60 participants with osteoarthritis were orally administered FlexCMOVE. Results showed remarkable improvement to pain, stiffness and physical function of the joints after 30 days.

Study 2: In this clinical trial, 30 adults with osteoarthritis (OA) (aged above 18 years) were orally administered 40 mg of UC-II® undenatured type II collagen for 6 months and the efficacy of UC-II® on cartilage thickness and breakdown was determined. UC-II® significantly increased knee cartilage thickness up to 17% and decreased cartilage breakdown. In addition, 30% of subjects stopped taking NSAIDs (medicine used to treat pain) after 12 weeks of UC-II® supplementation (PAIN, JOINTS, SPINE 11(3) (2021)).

Study 3: In this clinical trial, 60 adults affected by knee osteoarthritis (OA) (aged 40 to 75 years) were orally administered 40 mg of UC-II® undenatured type II collagen or placebo for 90 days and the combined effect of muscle strengthening exercises (physiotherapy) with UC-II® was determined. Muscle strengthening exercises (physiotherapy) improved pain, mobility, strength and function and the combination of physiotherapy and UC-II® resulted in more noticeable clinical improvement, especially in the long term. This suggests the beneficial effects of UC-II® supplementation on knee osteoarthritis (Muscles Ligaments Tendons J, 10(3), 481-492 (2020)).

Study 4: In this clinical trial, 291 adults with osteoarthritis (aged 28 to 79 years) were orally administered 40 mg of UC-II® undenatured type II collagen for 90 days and the effectiveness of UC-II® on osteoarthritis was determined using WOMAC (Western Ontario McMaster Osteoarthritis Index) and VAS (Visual Analogue scale) at day-30 (visit 2), day-60(visit 3) and day-90 (visit 4). Compared to baseline, treatment with UC-II® was associated with significant reduction in WOMAC score and VAS score (p < 0.0001), implying the efficacy of UC-II® in those affected by osteoarthritis.

Study 5: In this study, moderately arthritic dogs were orally administered with placebo(Group-I), 10 mg UC-II® (Group-II), 2000 mg GLU (glucosamine) + 1600 mg CHO(chondroitin) (Group-III) and UC-II + GLU + CHO (Group-IV) for 150 days. Results showed significant reduction (p < 0.05) in pain in Group-II, III and IV. Meanwhile, only Group-II group showed a decrease in arthritis associated pain, as indicated by significant increases in peak vertical force and impulse area. These findings suggest a marked reduction in arthritic pain in dogs treated with UC-II® with maximum improvement by day 150. In addition, UC-II®, glucosamine and chondroitin which work through different mechanisms of actions, were well tolerated over a period of 150 days (J Anim Physiol Anim Nutr (Berl). 96(5):770-7(2012)).

Study 6: In this study, horses with osteoarthritis-associated pain were orally administered placebo, UC-II® at 80, 120 or 160 mg UC-II, or glucosamine and chondroitin for 150 days. Results showed significant reduction in arthritic pain (p < 0.05) in horses receiving 120 or 160 mg UC-II®, while no change in arthritic condition in horses receiving placebo. UC-II® at 120 mg or 160 mg provided equal effects, and 120 mg UC-II® resulted in reduction in overall pain and pain upon limb manipulation. Despite horses treated with glucosamine and chondroitin showed significant (p < 0.05) reduction in pain, the efficacy was less compared to UC-II. These findings suggest the efficacy of UC-II® in managing
osteoarthritis-associated pain.

Study 7: In this study, dogs with osteoarthritis were orally administered placebo (group I), 10 mg UC-II® (group II), 2,000 mg glucosamine + 1,600 mg chondroitin (group III) and 10 mg UC-II® + 2,000 mg glucosamine + 1,600 mg chondroitin (group IV) for 120 days, followed by a 30-day withdrawal period. Results showed no change in arthritic conditions in dogs treated with placebo. Dogs receiving UC-II® showed maximum reductions in overall pain, pain upon limb manipulation and reductions in pain after 120 days. Meanwhile, glucosamine and chondroitin (group III) alleviated some pain, but combination with UC-II (group IV) provided significant reductions in pain and lameness. These findings suggest the efficacy of UC-II alone or in combination with glucosamine and chondroitin in alleviating osteoarthritis-associated pain.

Study 8: In this study, dogs affected by osteoarthritis were orally administered 40 mg UC-II® undenatured type II collagen or robenacoxib (R) (1mg/kg) daily for 30 days. Robenacoxib is a non-steroidal anti-inflammatory drug (NSAID) used in veterinary medicine to treat pain and inflammation in dogs and cats. The LOAD and MOBILITY scores were determined at baseline (T0) and 30 days after the beginning of the treatment (T30) with higher scores indicate more severe conditions. Results showed a significant reduction in LOAD and MOBILITY scores between T0 and T30 with similar magnitude among UC-II® and robenacoxib. These findings suggest that UCII® and robenacoxib similarly help improve mobility in dogs affected by osteoarthritis.

3) Support healthy cartilage

Study 1: In this study, monoiodoacetate (MIA) was used to induce osteoarthritis in the rats. The rats were divided into 3 groups: Control, MIA-induced rats treated with vehicle(control) and MIA-induced rats treated with UC-II® (4 mg/kg BW). After 7 days of UC-II® treatment, osteoarthritis was induced in rats by intra-articular injection of MIA (1 mg). In the articular (joint) cartilage, UC-II® inhibits the production of PGE2, which is associated with erosion of cartilage. Besides, the expression of inflammatory markers IL-1β, IL-6 and TNF-α decreased in UC-II supplemented rats. These findings suggest the beneficial effects of UC-II® in maintaining healthy cartilage and alleviating inflammation and pain in osteoarthritis.

Study 2: In this study, rats were subjected to partal medial meniscectomy tear (PMMT) surgery to induce osteoarthritis. Immediately after the surgery, the rats received vehicle (control) or oral daily dose of UC-II® at 0.66 mg/kg for a period of 8 weeks. PMMT surgery produced moderate osteoarthritis and the deterioration of articular cartilage negatively impacted the weight-bearing capacity of the limb. Nonetheless, immediate treatment with UC-II® preserved the weight-bearing capacity if the injured leg, preserved the integrity of the cancellous bone at bial metaphysis and limited the deterioration of articular cartilage. These findings suggest the UC-II® applied immediately after injury could help improve the mechanical function of the injured knee and protect against excessive deterioration of articular cartilage.

4) Improve exercise performance

Study 1: In this clinical trial, 55 healthy adults aged 30 to 65 years old, who had no prior history of arthritic disease or joint pain at rest but experienced joint discomfort with physical activity (stepmill exertion) were orally administered 40 mg of UC-II® denatured type II collagen or placebo once a day for 120 days. Compared to placebo and baseline, supplementation with UC-II® for 120 days resulted in significant improvement in average knee extension. Meanwhile, no significant change in knee extension observed in placebo group. In addition, UC-II® group could exercise for longer time before experiencing any initial joint discomfort at day 120 compared to baseline. These findings suggest daily supplementation with 40 mg of UC-II® could help improve knee joint extension, alleviate joint pain associated with strenuous physical activity and lengthen the duration of pain-free strenuous exertion.

Study 2: In this study, 40 healthy dogs (average 8 years) were orally administered 40 mg of UC-II® undenatured type II collagen or placebo for 90 days to evaluate its effect on inflammation and cartilage degeneration after exercise. After 2-weel loading, the dogs started 11-week endurance exercise regimen, which consists of 2 weekly run, staring at 5km and increasing incrementally to 8 km, with one final 16 km run. Compared to placebo, UC-II® resulted in greater activity per kilometer and average moving speed. Besides, IL-6 inflammatory marker was lower in UC-II® group at post 5 km, compared to placebo. Cartilage oligomeric matrix protein (COMP), which increased in blood indicates cartilage destruction, was lesser in dogs administered with UC-II® at post 16 km. Meanwhile, only placebo group had a significant increase in COMP from pre to post 16 km. These findings suggest that dogs administered with UC-II® helps mitigate inflammation and cartilage destruction during exercise.

Study 3: In this study, rats were divided into 3 groups: sedentary control, exercise (E) and exercise + UC-II® (4 mg/kg BW/day) (E + UC-II®). Compared to non-supplemented group, UC-II® group resulted in significant prolonged exhausive running time (p < 0.001). Compared to sedentary control, levels of serum creatinine kinase (an indirect marker of muscle damage) increased in the exercise group (p < 0.001). However, serum creatinine kinase levels were reduced in the E + UC-II® group compared to the E group (p < 0.01). Compared to control, E + UC-II® group showed significant reduction in serum lactate (cause of muscle soreness after exercise) (p < 0.01) and myoglobin (an indicator of muscle damage) (p < 0.0001). Besides, UC-II supplementation caused significant increases in antioxidants SOD and GSH-Px, as well as decrease in muscle inflammatory markers TNF-α and IL-1β than the control group. These findings suggest combination of exercise with UC-II® helps modulate muscle, antioxidant and inflammation status.

5) More effective than glucosamine and chondroitin

Study 1: In this clinical trial, 186 adults with knee osteoarthritis (aged 40 to 75 years) were orally administered 40 mg UC-II® undenatured type II collagen, 2,700 mg glucosamine hydrochloride and chondroitin sulfate (GC) or placebo for 180 days. Compared to placebo and GC, UC-II® significantly improved joint function, mobility and flexibility, as evaluated using total WOMAC, VAS scores and WOMAC pain, stiffness and physical function subscores. These findings suggest the efficacy of UC-II® in improving knee joint symptoms on knee osteoarthritis subjects.

Study 2: In this clinical trial, 52 adults with knee osteoarthritis aged 40 to 75 years old were orally administered 40 mg of UC-II® undenatured type II collagen or 2,700 mg of glucosamine HCl and chondroitin sulfate (GC) for 90 days. Compared to baseline, UC-II® administration was more effective to result in significant reduction in WOMAC and VAS scores at 90 days, while this effect was not observed in GC group. In addition, the Lequesne’s functional index, which is a questionnaire regarding pain, maximum distance walked and activities of daily living, showed that UC-II® reduced the score by 20% compared to 6% in GC group at the end of 90-day treatment. These findings suggest the efficacy of UC-II® in reducing joint pain, discomfort and immobility.